利莫那班临床前毒理学研究进展  

Preclinical toxicological study of rimonabant

作　　者：原野[1] 吴纯启[1] 廖明阳[1] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国新药杂志》2009年第5期399-402,共4页Chinese Journal of New Drugs

摘　　要：利莫那班(rimonabant)为首个大麻素Ⅰ型受体(CB1)抑制剂类减肥药,有很好的减肥效果。但近期的研究表明利莫那班可增加抑郁、焦虑、自杀等严重精神不良反应的发生率。文中扼要综述了利莫那班在次要药效学和安全性药理学、一般毒性、毒性靶器官系统、遗传毒性、致癌性和生殖毒性以及刺激性、依赖性等方面的临床前毒理学特征,以促进具有更高安全性的大麻素Ⅰ型受体拮抗剂的开发。Rimonabant is the first antagonist of cannabinoid receptor Ⅰ as a weight-reducing drug with satisfying effect.However,it is reported that rimonabant can increase the incidence of some severe psychological adverse effects such as depression,dysphoria and suicide.In this paper,the secondary pharmacodynamics,safety pharmacology,general toxicology,toxicity target organ,genotoxicity,carcinogenicity,teratotoxicity and other toxicity of rimonabant were summarized to demonstrate its preclinical toxicology.Avoiding these toxicities will facilitate the research and development of more safe cannabinoid receptor Ⅰ antagonists.

关 键 词：利莫那班 次要药效学 临床前毒理学 

分 类 号：R971[医药卫生—药品]